Sanofi Pasteur and International Vaccine Institute Partner Against Dengue

February 21, 2011

LYON, France, February 21, 2011 /PRNewswire-FirstCall/ — Sanofi Pasteur,
the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY),
announced today that it is partnering with the International Vaccine
Institute (IVI) to support the recently launched Dengue Vaccine Initiative
(DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to
move dengue vaccination higher on the global health agenda.

Currently, there is no specific treatment available for dengue fever,
which is a threat to nearly half of the world’s population and a public
health priority in many countries of Latin America and Asia where epidemics
occur. Of the estimated 220 million people infected annually, two
million-mostly children-develop dengue hemorrhagic fever (DHF), a severe form
of the disease[1]. DHF is a leading cause of hospitalization, placing
tremendous pressure on strained medical resources and having a heavy economic
and societal impact.

“Each year, an estimated two million people with dengue hemorrhagic fever
require hospitalization representing a significant burden on the fragile
healthcare systems of developing and endemic nations,” said Dr. Ragnar
, Chairman of the Board of Trustees of IVI. “With a dengue vaccine on
the short term horizon, this collaboration will focus on accelerating its
adoption and introduction and on making it accessible to those at highest
risk of dengue.”

The International Vaccine Institute (IVI) announced the launch of the DVI
on February 10, in collaboration with the Sabin Vaccine Institute, the Johns
Hopkins University
, and the World Health Organization, to support development
of vaccines to control dengue fever.

“The fight against dengue requires a strong global commitment from all
public health partners. The first dengue vaccine is now in the final stages
of development. The IVI will be a key player in facilitating discussions
among policy makers, with the objective of ensuring that once licensed the
vaccine will be made available to those populations that need it most in a
timely manner,” stated Olivier Charmeil, Senior Vice President,
sanofi-aventis, Vaccines.

About International Vaccine Institute

The International Vaccine Institute is an international organization
devoted exclusively to developing and introducing new and improved vaccines
for the world’s poorest people, especially children in developing countries.
The IVI conducts research in 30 countries in Asia, Africa, and Central and
South America on vaccines against diarrheal infections, bacterial meningitis
and pneumonia, Japanese encephalitis, and dengue fever, and develops new and
improved vaccines, delivery routes and adjuvants at its headquarters in
Seoul, Korea.

About Dengue Vaccine Initiative

The Dengue Vaccine Initiative (DVI) was established in 2010 to build on
the work of the Pediatric Dengue Vaccine Initiative and to further awareness
of the need to support the development and use of dengue vaccines. The goal
of the DVI is to accelerate the introduction of safe and broadly protective
vaccines into the national immunization programs of endemic and developing
countries. DVI works with scientists, vaccine experts and policy makers from
concept to implementation, promoting the development of dengue vaccines while
also advocating with governments worldwide to ensure the swift adoption and
distribution of a vaccine to those most in need.

Sanofi Pasteur’s global dengue vaccine clinical study program

Sanofi Pasteur’s candidate dengue vaccine-which targets all four virus
serotypes- is in Phase 3 clinical study. Phase 3 studies are the ultimate
steps in the clinical development of a vaccine before it is submitted to
regulatory authorities for evaluation for market authorization. Sanofi
Pasteur candidate dengue vaccine has been evaluated in clinical studies
(Phase 1, 2) in adults and children in the U.S., Asia and Latin America.
Overall, a balanced immune response against all four serotypes was observed
after three doses of the vaccine. The vaccine is well tolerated with a
similar safety profile after each dose.[2]

Clinical studies in adults and children are ongoing in Mexico, Colombia,
Honduras, Puerto Rico, Peru, the Philippines, Vietnam, Singapore, Australia,
and Thailand.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY). For more information, please visit: http://www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provides
more than 1 billion doses of vaccine each year, making it possible to
immunize more than 500 million people across the globe. A world leader in the
vaccine industry, Sanofi Pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The company’s heritage, to create
vaccines that protect life, dates back more than a century. Sanofi Pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR 1 million in research and development. For more
information, please visit: http://www.sanofipasteur.com or

Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential and statements regarding future performance.
Forward-looking statements are generally identified by the words “expects,”
“anticipates,” “believes,” “intends,” “estimates,” “plans” and similar
expressions. Although sanofi-aventis’ management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the
FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could
affect the availability or commercial potential of such products candidates,
the absence of guarantee that the products candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives, the Group’s ability to benefit from external growth
opportunities as well as those discussed or identified in the public filings
with the SEC and the AMF made by sanofi-aventis, including those listed under
“Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended
December 31, 2009. Other than as required by applicable law, sanofi-aventis
does not undertake any obligation to update or revise any forward-looking
information or statements.

[1] PDVI Newsletter No. 7, April 2010 accessible at

[2] Saville et al, Clinical development of a tetravalent dengue vaccine
for endemic areas, ICID Miami, March 2010; Lang et al, Toward a tetravalent
dengue vaccine in Brazil, Tropical Medicine meeting, Iguacu Falls, March 2010


SOURCE Sanofi Pasteur

Source: newswire

comments powered by Disqus